What is Immutep?
Established in 2001 and headquartered in Sydney, New South Wales, Immutep is at the forefront of developing novel treatments for cancer. The company's core focus lies in harnessing the power of the immune system to combat malignancies, positioning it within the rapidly evolving field of immuno-oncology. Its strategic financing rounds indicate a strong investor confidence in its scientific approach and market potential.
How much funding has Immutep raised?
Immutep has raised a total of $140M across 3 funding rounds:
Share Placement
$7M
Other Financing Round
$80M
Other Financing Round
$53M
Share Placement (2019): $7M, investors not publicly disclosed
Other Financing Round (2023): $80M, investors not publicly disclosed
Other Financing Round (2024): $53M, investors not publicly disclosed
What's next for Immutep?
The recent major enterprise-level funding suggests Immutep is poised for significant expansion and further development of its lead drug candidates. This capital injection will likely accelerate clinical trials, enhance manufacturing capabilities, and potentially support strategic partnerships or acquisitions. The company's trajectory indicates a move towards later-stage development and commercialization, aiming to bring innovative cancer immunotherapies to patients.
See full Immutep company page
